4dmt highlights robust and durable clinical activity for 4d-150 and design of 4front phase 3 program at 4d-150 wet amd development day

Emeryville, calif., sept. 18, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced data showing continued robust and durable clinical activity, based on longest interim follow-up data from the phase 1/2 prism clinical trial, and 4front phase 3 study design, which will be presented at its 4d-150 wet amd development day.
AMD Ratings Summary
AMD Quant Ranking